Skip to content

Concentra 集团

US · CON #2185 按市值排名 上市于 2024
38.54 -0.61 -1.56%
实时 - 追踪5344个代码 - 心跳于389秒前 · 2026-10-16 20:01

✦ 量化合理价值 计算方式说明

高于合理价值
18.61 合理价值 ≈ 22.68 26.75
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为18.61-26.75。
  • 当前价格比按平均倍数计算的合理价值(22.68)高69.9%。

估值 各估值倍数与自身5年区间的对比

市净率 9.73 高于历史水平 第88百分位
5年平均 7.64 · 在Medical Care Facilities中排名第37/40
市盈率 23.48 高于历史水平 第100百分位
5年平均 17.45 · 前瞻 20.75 · 在Medical Care Facilities中排名第18/30
市销率 2.03 高于历史水平 第100百分位
5年平均 1.45 · 前瞻 1.92 · 在Medical Care Facilities中排名第43/50

同业对比 Medical Care Facilities

公司 市值 市盈率(TTM) 市净率 股息率
Concentra 集团 (CON) 4.91B 24.86 10.30 0.65%
HCA Healthcare (HCA) 99.34B 15.39 -14.96 0.65%
Tenet Healthcare (THC) 21.52B 10.33 4.62 0.00%
Encompass Health (EHC) 12.61B 20.83 4.86 0.59%
DaVita (DVA) 11.95B 15.44 -15.62 0.00%
Fresenius Medical Care (FMS) 11.80B 11.90 0.84 3.85%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值34.22 经济护城河Narrow 不确定性Medium

当前股价高于晨星合理价值估算11.2%。

合理价值

Concentra Group Holdings Parent Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $34.22 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.

The firm's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 10.5% lies in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

Conversely, the firm's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's assets turnover ratio of 0.8, a core component of profitability, ranks in the top 40% globally. This exemplifies its robust ability to scale the benefits it wrings out of a fixed set of assets and inventory. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:01:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

Concentra 集团 讨论区 0 条评论

发表评论